IV vitamin drips: what does the evidence actually show?

Intravenous vitamin clinics have proliferated across the UK and internationally, offering drips variously marketed for energy, immune support, skin brightening, hangover recovery, and anti-ageing. Prices typically range from £100 to £500 per session. The market has been valued at over £10 billion globally and is growing. The NHS Medical Director issued a public warning about the potential health risks of commercial IV drips as far back as 2019. The evidence base for the wellness claims has not meaningfully expanded in terms of high-quality trials since then.

This article examines what the clinical evidence actually shows for the main categories of IV vitamin therapy, separates the legitimate medical uses from the wellness marketing, and addresses the safety risks that the industry routinely minimises.

The core claim and why it is misleading

The central argument made by IV vitamin clinics is that the intravenous route delivers nutrients directly to the bloodstream, bypassing the digestive system and achieving higher concentrations than oral supplementation. This is pharmacologically true for some nutrients. It is the basis for legitimate medical use of IV nutrition in specific clinical contexts. It does not, by itself, constitute evidence that healthy people benefit from IV vitamin administration.

Higher bioavailability only matters if there is a deficit to correct or a specific pharmacological target to reach. This is a fundamental principle that the wellness marketing consistently obscures: in nutrition, the physiological effects of supplementation are largely confined to populations with deficiency or insufficiency. For a person with normal gut absorption and no micronutrient deficiency, administering vitamins intravenously has not been shown to produce additional benefit over adequately supplying those nutrients through diet or oral supplementation, and no effect size for general wellness outcomes has been demonstrated in controlled trials. The body maintains tight homeostatic regulation of most micronutrients and excretes what it does not need. Achieving a temporarily elevated serum vitamin level is not equivalent to achieving a clinical benefit.

A 2023 review published in the Drug and Therapeutics Bulletin, one of the BMJ group's evidence evaluation publications, concluded that there is a lack of high-quality evidence to suggest that high-dose vitamin infusions are necessary or offer any health benefit in the absence of a specific vitamin deficiency or medical condition. This assessment reflects the current state of the literature accurately.

When intravenous nutrition is medically appropriate

Before examining the wellness claims, it is worth being clear about where IV vitamins have a genuine and well-supported clinical role.

Intravenous administration of vitamins and minerals is standard medical practice in specific circumstances. Patients with malabsorption syndromes, including coeliac disease, Crohn's disease, short bowel syndrome, and other conditions that substantially impair nutrient absorption, may require parenteral nutrition because the oral route cannot deliver sufficient nutrients reliably. Wernicke's encephalopathy, a neurological emergency caused by acute thiamine deficiency most commonly seen in alcohol dependence, requires urgent IV thiamine because oral administration is too slow and unreliable in that context. Critically ill patients in intensive care settings may receive IV micronutrients as part of broader nutritional support. Vitamin B12 deficiency caused by pernicious anaemia, where intrinsic factor is absent and oral absorption is impaired, is treated with intramuscular B12 injections.

In all of these cases, the intravenous or intramuscular route is chosen because the oral route is compromised or insufficient. The route is selected on clinical grounds, not as a premium delivery mechanism for otherwise-available nutrients. Notably, a systematic review of B12 supplementation published in 2025 found that oral therapy showed similar efficacy to intramuscular injections in patients with confirmed deficiency, better tolerability, and lower cost, reinforcing that even in deficiency states, the parenteral route is not always necessary.

Myers' cocktail and general wellness infusions

The Myers' cocktail is the most widely marketed IV vitamin preparation in wellness settings. It typically contains a combination of magnesium, calcium, B vitamins, and vitamin C in varying proportions, mixed with sterile water and administered over twenty to sixty minutes. It was developed by an American physician, John Myers, based on his clinical observations in the 1970s and 1980s, and was described by Alan Gaby in a 2002 case series in the journal Alternative Medicine Review. That paper documented anecdotal responses in a range of conditions but did not constitute controlled clinical evidence.

The controlled trial evidence for the Myers' cocktail is extremely limited. A single randomised, double-blind, placebo-controlled pilot study examined its use in fibromyalgia, published in the Journal of Alternative and Complementary Medicine by Ali and colleagues in 2009. This enrolled 34 adults and found that while both groups improved over the eight-week trial period, there was no statistically significant difference between the active and placebo groups on the primary outcome of tender point index at week 8 or week 12. Both groups showed reductions in pain scores from baseline, which the authors attributed in part to a substantial placebo response. The study was not powered to detect small effects and the authors described it as establishing feasibility and safety, noting that the efficacy of the Myers' cocktail relative to placebo remained uncertain. This is the most rigorous controlled evidence available for the Myers' cocktail to date. It does not support the efficacy claims made in wellness marketing.

No controlled trials have examined the Myers' cocktail for energy enhancement, immune support, stress reduction, skin health, or any of the other claims routinely made by wellness clinics. There is no clear evidence that this gap is currently being addressed by high-quality trials: a 2021 review that searched the medical literature for evidence on IV vitamin therapy outside conventional medical settings found 155 articles, consisting mostly of case reports or self-reports and uses in adjunctive treatment for specific medical conditions. No evidence-based guidelines were found for the general wellness uses now marketed commercially.

The Merck Manual's professional edition notes directly that despite widespread commercial use, there is a lack of supporting evidence and a lack of regulatory oversight for IV vitamin therapy marketed for wellness purposes.

IV glutathione for skin lightening

IV glutathione infusions are marketed specifically for skin lightening and are widely available in wellness clinics, particularly in parts of Asia, the Middle East, and increasingly in Western markets. Glutathione is an endogenous antioxidant produced by the body and is involved in melanin synthesis pathways, which provides a mechanistic basis for the proposed skin-lightening effect.

The clinical evidence does not support the use of IV glutathione for this purpose. No controlled trials of IV glutathione for skin lightening have demonstrated clinically meaningful or sustained efficacy. A 2012 randomised controlled trial by Arjinpathana and Asawanonda in the Journal of Dermatological Treatment examined topical rather than IV glutathione and found a modest effect on skin melanin index compared with placebo; this finding cannot be extrapolated to the IV route. The WHO has noted concerns about the use of IV glutathione for cosmetic skin lightening on the grounds of both insufficient efficacy evidence and safety uncertainty.

The safety profile of IV glutathione for this purpose is poorly characterised. Reported adverse effects in case reports and case series include thyroid dysfunction and renal toxicity at higher doses. The practice has attracted regulatory warnings in several countries including the Philippines, Canada, and the United States, where the FDA has warned that the safety and efficacy of glutathione IV injections for skin lightening have not been established.

The bioavailability argument examined more closely

One area sometimes conflated with wellness IV therapy is high-dose intravenous vitamin C in oncology research. This operates at fundamentally different doses (typically 10 to 100 grams per infusion), in a fundamentally different population, and for a fundamentally different pharmacological purpose. It is outside the scope of this article and should not be read as supporting the general wellness use of IV vitamin preparations.

For the doses and preparations used in commercial wellness drips, the bioavailability argument does not hold. For water-soluble vitamins such as vitamin C and the B vitamins, the body excretes excess amounts in urine. When plasma vitamin C concentrations are elevated beyond the kidney's reabsorption threshold, the excess is simply excreted. In healthy individuals with normal absorption, oral vitamin C at sufficient doses achieves saturation of tissue stores. The argument that IV administration delivers more therefore misses the point that having more in the bloodstream than tissues can use or kidneys can efficiently excrete has not been shown to constitute an additional benefit.

The bioavailability argument is legitimate in the specific contexts where it applies: genuinely impaired gut absorption, or pharmacological dosing for specific mechanistic purposes. It is not a general justification for bypassing the oral route in people who are replete and absorbing normally.

Safety: the understated risk

The wellness industry's communication about safety is consistently inadequate. The risks of IV vitamin therapy are typically presented as minimal, rare, and manageable. A more accurate characterisation is that the risks are real, documented, and disproportionate to the absence of established benefit in healthy individuals.

It is important to be clear about the evidence base for the safety concerns described below. Much of the published safety literature consists of case reports and regulatory warnings rather than large prospective datasets, which means the true population-level incidence of serious adverse events is not well characterised and is likely underreported given the absence of mandatory reporting infrastructure in this sector. This uncertainty about incidence does not, however, make the risks clinically negligible. In the absence of demonstrated benefit, even low-frequency serious risks become clinically significant: a procedure that offers no established benefit and carries a non-zero risk of sepsis or serious complication cannot be justified on a risk-benefit basis regardless of how rarely harm occurs.

Any intravenous procedure creates a direct route into the bloodstream. Bloodstream infection and sepsis are the most serious risks. Sepsis is a medical emergency with a significant mortality rate even with prompt treatment. A case report published in a peer-reviewed journal in 2025 documented a SIRS-like reaction consistent with culture-negative sepsis in a previously healthy 21-year-old male following an unregulated IV supplement preparation obtained outside medical oversight, requiring hospitalisation and broad-spectrum antibiotics. An NBC News investigation published in January 2024 documented a growing number of adverse events at unregulated wellness clinics, including a case of drug-resistant infection requiring hospitalisation following an IV drip at a commercial med spa. These are individual cases, not incidence data, but they illustrate documented real-world harm.

The FDA has highlighted concerns about compounding of drug products by medical offices and clinics under unsanitary conditions. Between 2020 and 2023, Poland's Patients' Ombudsman issued 36 decisions recognising instances of vitamin infusions administered outside current medical knowledge, following a formal statement that administering vitamin infusions without prior diagnosis of a deficiency violates patients' collective rights to quality health services.

Beyond infection, the documented risks include:

Phlebitis and thrombophlebitis, meaning inflammation of the vein wall and clot formation, which can occur with repeated use of the same vein or with preparation-related vein irritation. Air embolism is a rare but potentially fatal complication of any intravenous procedure if air enters the line. Fluid overload is a particular risk in individuals with undiagnosed or known cardiac or renal compromise, where rapid infusion of large volumes can precipitate acute heart failure or pulmonary oedema. Electrolyte disturbance can result from high-dose magnesium infusion, with cardiac conduction effects in susceptible individuals. High-dose vitamin C can increase urinary oxalate excretion and has been associated with acute oxalate nephropathy in individuals with pre-existing renal impairment or undiagnosed predisposition. Hypersensitivity reactions, including anaphylaxis, can occur to components of infused preparations.

These risks exist in well-regulated clinical settings. In unregulated wellness environments with variable staff training, inconsistent sterile technique, and no pre-procedure medical assessment, the risk profile is materially worse.

The regulation gap

A central problem with the IV wellness clinic industry is the regulatory environment in which it operates. In the UK, intravenous administration of medicines is a prescription-only activity, meaning a registered medical professional must be involved. In practice, the nature and depth of pre-procedure medical assessment across commercial clinics is highly variable. No standardised guidelines for wellness IV therapy have been published by UK regulatory bodies, and there is no mandatory adverse event reporting framework specific to this sector comparable to that governing equivalent procedures in NHS or registered clinical settings.

This creates a situation in which a procedure with real medical risks is being performed routinely outside the safety infrastructure that governs comparable procedures in medical settings. The populations attending wellness IV clinics are not consistently screened for the conditions that would make IV infusion higher risk, including renal impairment, cardiac disease, and G6PD deficiency, the latter being a recognised contraindication to high-dose vitamin C.

What can reasonably be concluded

The available evidence does not support the use of intravenous vitamin drips for energy enhancement, immune support, skin health, stress reduction, hangover recovery, or general wellness in otherwise healthy people. For these indications, the clinical trial evidence is absent or, where it exists, has not demonstrated benefit over placebo, and no effect size for any of these outcomes has been established. The bioavailability argument does not substitute for clinical evidence of benefit. The physiological rationale for bypassing the oral route in people with normal absorption and no documented deficiency is not established.

There are specific and legitimate clinical contexts in which IV vitamin administration is appropriate and evidence-supported: malabsorption syndromes, Wernicke's encephalopathy, critical illness, and specific deficiency states where the oral route is inadequate. These uses bear no meaningful resemblance to a wellness drip administered to a healthy person in a commercial clinic.

The safety risks are real and include sepsis, phlebitis, fluid overload, electrolyte disturbance, and renal complications in susceptible individuals. These risks are being routinely minimised in commercial wellness settings that lack the regulatory framework, pre-procedure assessment, and adverse event reporting that equivalent procedures would require in a medical context. The risks are not justified by the absence of established benefit.

The appropriate clinical question before any IV procedure is not "could this help?" but "does the evidence show it helps, does this person need it, and does the benefit exceed the risk?" For wellness IV vitamin administration in healthy people, current evidence cannot answer the first question affirmatively and cannot adequately define the second. The third question therefore cannot be resolved in favour of proceeding.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.

Key references

Gaby, A.R. (2002) 'Intravenous nutrient therapy: the "Myers' cocktail"', Alternative Medicine Review, 7(5), pp. 389-403. PMID: 12410623

Ali, A., Njike, V.Y., Northrup, V. et al. (2009) 'Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study', Journal of Alternative and Complementary Medicine, 15(3), pp. 247-257. DOI: 10.1089/acm.2008.0410

Drug and Therapeutics Bulletin (2023) 'Intravenous vitamin injections: where is the evidence?', Drug and Therapeutics Bulletin, 61(10), pp. 151-155. DOI: 10.1136/dtb.2023.000006

Arjinpathana, N. and Asawanonda, P. (2012) 'Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study', Journal of Dermatological Treatment, 23(2), pp. 97-102. DOI: 10.3109/09546634.2011.590792

Naidu, S.A.G., Clemens, R.A. and Naidu, A.S. (2023) 'To IV or not to IV: the science behind intravenous vitamin therapy', PMC12182718. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12182718/

Tkachenko, O., Davydenko, I., Matviychuk, O. et al. (2024) 'Health professionals' perspectives on commercially available intravenous nutrient therapies: a preliminary report', PMC10855962. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10855962/

For related evidence on specific nutrients discussed in this article, see the Vitamin C, Magnesium, Vitamin B12, and Glutathione entries and the NAD+ Infusions article in the Evidentia library.